TBRIA (calcitonin-salmon) for the Treatment of Postmenopausal Osteoporosis
TBRIA (calcitonin-salmon [rDNA origin] delayed release tablet) is the first oral recombinant salmon calcitonin, developed by Tarsa Therapeutics, for the treatment of postmenopausal osteoporosis. (Source: Drug Development Technology)
Source: Drug Development Technology - November 23, 2015 Category: Pharmaceuticals Source Type: news
Teriparatide Manages Surgical HypoparathyroidismTeriparatide Manages Surgical Hypoparathyroidism
Use of teriparatide (parathyroid hormone 1-34) in patients with postsurgical hypoparathyroidism showed rapid increase in serum calcium and a decrease in phosphate, despite reduced calcium and vitamin D supplementation. Quality of life also improved. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - August 6, 2015 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Teriparatide to Denosumab Switch Helpful in OsteoporosisTeriparatide to Denosumab Switch Helpful in Osteoporosis
In postmenopausal osteoporotic women, changing from teriparatide to denosumab benefits bone mineral density (BMD) but switching from denosumab to teriparatide may result in bone loss, according to new research. Reuters Health Information (Source: Medscape ObGyn and Womens Health Headlines)
Source: Medscape ObGyn and Womens Health Headlines - July 15, 2015 Category: OBGYN Tags: Orthopaedics News Source Type: news
Zomacton (somatropin rDNA origin) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 2, 2015 Category: Drugs & Pharmacology Source Type: news
teriparatide (Forteo)
Title: teriparatide (Forteo)Category: MedicationsCreated: 3/2/2005 12:00:00 AMLast Editorial Review: 6/19/2015 12:00:00 AM (Source: MedicineNet Womens Health General)
Source: MedicineNet Womens Health General - June 19, 2015 Category: OBGYN Source Type: news
teriparatide (Forteo)
Title: teriparatide (Forteo)Category: MedicationsCreated: 3/2/2005 12:00:00 AMLast Editorial Review: 6/19/2015 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - June 19, 2015 Category: Drugs & Pharmacology Source Type: news
Teriparatide Treatment Patterns Impact Risk of Fragility Fractures
No abstract available (Source: Lippincott’s Bone and Joint Newsletter)
Source: Lippincott’s Bone and Joint Newsletter - April 27, 2015 Category: Orthopaedics Tags: CME Article Source Type: news
Toujeo for the Treatment of Type 1 and Type 2 Diabetes
Toujeo (insulin glargine [rDNA origin]) is an insulin injection approved for the treatment of type 1 and type 2 diabetes to improve glycaemic control in adult patients. (Source: Drug Development Technology)
Source: Drug Development Technology - April 16, 2015 Category: Pharmaceuticals Source Type: news
Ferring Pharmaceuticals Receives FDA Approval for Growth Hormone Name Change, Acquires Zomacton [somatropin (rDNA origin)]
PARSIPPANY, N.J., March 31, 2015 – Ferring Pharmaceuticals Inc. today announced U.S. Food and Drug Administration (FDA) approval of a name change enabling its newly acquired recombinant human growth hormone to be marketed in the U.S. as Zomacton... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 1, 2015 Category: Pharmaceuticals Source Type: news
Monthly News Roundup - February 2015
Sanofi Receives FDA Approval for Basal Insulin Toujeo
The U.S. Food and Drug Administration has approved Sanofi’s Toujeo (insulin glargine [rDNA origin], a once-daily long-acting basal insulin for adults with type 1 or type 2 diabetes. In the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 27, 2015 Category: Pharmaceuticals Source Type: news
Sanofi's diabetes treatment Toujeo obtains FDA approval
Sanofi has received approval from the US Food and Drug Administration (FDA) for its Toujeo (insulin glargine [rDNA origin] injection, 300U/mL). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - February 26, 2015 Category: Pharmaceuticals Source Type: news
Saxenda (liraglutide) for the Treatment of Obesity
Saxenda (liraglutide (rDNA origin)) is a newly approved injection for the treatment of obesity and chronic weight management. (Source: Drug Development Technology)
Source: Drug Development Technology - February 10, 2015 Category: Pharmaceuticals Source Type: news
Saxenda (Liraglutide [rDNA Origin]) Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 6, 2015 Category: Drugs & Pharmacology Source Type: news
2014 New Drug Approvals Hit 18-Year High
2014 was a good year for pharmaceutical innovation – the best, in fact, since the industry’s all-time record of 1996. FDA approved a total of 44 drugs – 39 by CDER, and 5 by CBER (Exhibit 1). As usual, this total excludes imaging agents (i.e., Lumason and Neuraceq), and only includes the biological drugs from CBER that are of rDNA origin. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - January 2, 2015 Category: Pharmaceuticals Authors: Bernard Munos Source Type: news
FDA Approves New Weight Loss Drug (FREE)
By Kelly Young
Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM
The FDA has approved liraglutide (rDNA origin) injection (marketed as … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - December 24, 2014 Category: Primary Care Source Type: news
